Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma

被引:6
|
作者
Motta, Juliana Maria [1 ]
Hassan, Hebatallah [2 ]
Ibrahim, Sherif Abdelaziz [2 ]
机构
[1] Univ Fed Rio De Janeiro, Hosp Univ Clementino Fraga Filho, Inst Bioquim Med Leopoldo De Meis, BR-21941 Rio De Janeiro, Brazil
[2] Cairo Univ, Fac Sci, Dept Zool, Giza 12613, Egypt
关键词
syndecans; breast cancer; tumor microenvironment; epithelial-mesenchymal transition; nuclear hormone receptors; microRNAs; exosomes; therapeutic perspectives; HEPARAN-SULFATE PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; CANCER CELL MOTILITY; ESTROGEN-RECEPTOR; FUNCTIONAL-PROPERTIES; ER-ALPHA; NUCLEAR RECEPTORS; INTEGRIN ACTIVITY; EXPRESSION; BETA;
D O I
10.3390/cancers15061794
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Syndecans (SDCs; SDC1 to 4) are integral cell surface proteoglycans that are expressed normally on various types of mammalian tissues. In cancer, SDCs' expression is dysregulated, impacting the onset and progression of cancer by modulating pivotal signaling pathways involved in biological and molecular functions. In this review, we highlight the key roles of SDCs in breast cancer pathogenesis, addressing the prognostic value and the critical molecular regulators of SDC expression, as well as different SDC-centered therapeutic perspectives. Syndecans (SDC1 to 4), a family of cell surface heparan sulfate proteoglycans, are frequently expressed in mammalian tissues. SDCs are aberrantly expressed either on tumor or stromal cells, influencing cancer initiation and progression through their pleiotropic role in different signaling pathways relevant to proliferation, cell-matrix adhesion, migration, invasion, metastasis, cancer stemness, and angiogenesis. In this review, we discuss the key roles of SDCs in the pathogenesis of breast cancer, the most common malignancy in females worldwide, focusing on the prognostic significance and molecular regulators of SDC expression and localization in either breast tumor tissue or its microenvironmental cells and the SDC-dependent epithelial-mesenchymal transition program. This review also highlights the molecular mechanisms underlying the roles of SDCs in regulating breast cancer cell behavior via modulation of nuclear hormone receptor signaling, microRNA expression, and exosome biogenesis and functions, as well as summarizing the potential of SDCs as promising candidate targets for therapeutic strategies against breast cancer.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma
    Kitajim, Kazuhiro
    Yamano, Toshiko
    Fukushima, Kazuhito
    Miyoshi, Yasuo
    Hirota, Seiichi
    Kawanaka, Yusuke
    Miya, Mouri
    Doi, Hiroshi
    Yamakado, Koichiro
    Hirota, Shozo
    EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (05) : 943 - 949
  • [42] Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance
    Wang, Chenglong
    Ye, Qian
    Cao, Yijia
    Tan, Juan
    Wang, Fei
    Jiang, Jin
    Cao, Youde
    ONCOLOGY LETTERS, 2018, 15 (01) : 213 - 220
  • [43] DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma
    Guillaume B. Cardin
    Monique Bernard
    Francis Rodier
    Apostolos Christopoulos
    Scientific Reports, 11
  • [44] DCBLD1 is associated with the integrin signaling pathway and has prognostic value in non-small cell lung and invasive breast carcinoma
    Cardin, Guillaume B.
    Bernard, Monique
    Rodier, Francis
    Christopoulos, Apostolos
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] Can 18F FDG PET/CT be a new tool in the prognostic armamentarium of carcinoma breast ? Correlating 18F FDG uptake values with histopathological markers in primary breast cancer
    Ravina, M.
    Chauhan, M.
    Jacob, M.
    Pandit, A.
    Sanchety, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S622 - S622
  • [46] Identification of the prognostic and therapeutic values of cyclin E1 (CCNE1) gene expression in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: A database mining approach
    Ullah, Md. Asad
    Farzana, Maisha
    Islam, Md. Shariful
    Moni, Ripa
    Zohora, Umme Salma
    Rahman, Mohammad Shahedur
    HELIYON, 2022, 8 (09)
  • [47] Hormonal Receptor and Her-2/Neu Status Evaluation in Cytology Specimens of Primary and Metastatic Breast Carcinoma - Does It Have Diagnostic, Prognostic or Therapeutic Implications?
    Ghosh, Chandrani
    Husain, Mujtaba
    Kanhere, Rujuta
    Bandyopadhyay, Sudeshna
    Feng, Jenin
    Shi, Dongping
    Giorgadze, Tamar
    CANCER CYTOPATHOLOGY, 2009, 117 (05) : 361 - 361
  • [48] Netrin Family Genes as Prognostic Markers and Therapeutic Targets for Clear Cell Renal Cell Carcinoma: Netrin-4 Acts through the Wnt/β-Catenin Signaling Pathway
    Ke, Shuai
    Guo, Jiayu
    Wang, Qinghua
    Shao, Haoren
    He, Mu
    Li, Tao
    Qiu, Tao
    Guo, Jia
    CANCERS, 2023, 15 (10)
  • [49] The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy
    Guney Eskiler, Gamze
    Kazan, Nur
    Haciefendi, Ayten
    Deveci Ozkan, Asuman
    Ozdemir, Kayhan
    Ozen, Mirac
    Kocer, Havva Belma
    Yilmaz, Fahri
    Kaleli, Suleyman
    Sahin, Elvan
    Bilir, Cemil
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (02): : 460 - 472
  • [50] The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy
    Gamze Guney Eskiler
    Nur Kazan
    Ayten Haciefendi
    Asuman Deveci Ozkan
    Kayhan Ozdemir
    Mirac Ozen
    Havva Belma Kocer
    Fahri Yilmaz
    Suleyman Kaleli
    Elvan Sahin
    Cemil Bilir
    Clinical and Translational Oncology, 2023, 25 : 460 - 472